FDA reviewing Valeant's psoriasis candidate Jemdel

The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA accepted for review an NDA for Jemdel (IDP-122) to treat plaque psoriasis. Its PDUFA date is Oct. 5.

Jemdel is a lotion containing 0.01% halobetasol propionate, a synthetic corticosteroid...